Frequency and Predictive Factors of Hypoglycemia in Patients Treated With rhIGF-1: Data From the Eu-IGFD Registry.
Peter Bang, Michel Polak, Artur Bossowski...
https://pubmed.ncbi.nlm.nih.gov/37579214/Actively Recruiting
Led by Esteve Pharmaceuticals, S.A. · Updated on 2026-02-06
500
Participants Needed
58
Research Sites
N/A
Total Duration
Researchers are conducting a global registry to monitor the long-term safety and effectiveness of Increlex therapy in children and adolescents with Severe Primary Insulin-like Growth Factor-1 Deficiency SPIGFD. This observational, non-interventional registry collects data from multiple countries including Austria, France, Germany, Italy, Poland, Spain, Sweden, the United Kingdom, and the USA. The main goal is to gather safety information during treatment and for at least five years after treatment ends. The registry includes participants who are starting, planning to start, or already receiving Increlex treatment as per local prescribing information. Increlex mecasermin is given as an injection with doses ranging from 40 to 120 mcgkg twice daily, prescribed by a physician. Data may be collected retrospectively for those already on treatment. The study tracks participants over long periods to observe treatment exposure, dose, and various health outcomes related to growth and development. Participants will be monitored for adverse events, including serious events and neoplasia, during treatment and up to five years afterward. Researchers will also assess changes in height, bone age, body mass index, pubertal stage, and quality of life. Biological markers like growth hormone and IGF-1 levels will be measured periodically. The registry collects comprehensive data on safety, effectiveness, and other health indicators to better understand outcomes in children and adolescents receiving Increlex therapy.
CONDITIONS
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
E
Esteve Global Clinical Development
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Esteve Pharmaceuticals, S.A.
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years or until final adult height is achieved
Participants who are starting, planning to start, or currently receiving Increlex® therapy for severe primary IGF-1 deficiency are observed to monitor long-term safety and effectiveness of the treatment.
Periodic visits throughout the study duration
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Peter Bang, Michel Polak, Artur Bossowski...
https://pubmed.ncbi.nlm.nih.gov/37579214/Peter Bang, Michel Polak, Valérie Perrot...
https://pubmed.ncbi.nlm.nih.gov/35250870/Marta Ramon-Krauel, Michel Polak, Mohamad Maghnie...
https://pubmed.ncbi.nlm.nih.gov/40626687/Peter Bang, Joachim Woelfle, Valerie Perrot...
https://pubmed.ncbi.nlm.nih.gov/33434161/Esteve Pharmaceuticals, S.A.
Lead Sponsor